@article{677810f4d7b54504ad31a8341bfc2e75,
title = "Vorapaxar, combination antiplatelet therapy, and stroke",
keywords = "PAR-1 receptor, acute coronary syndrome, antiplatelet, intracerebral hemorrhage, peripheral arterial disease, platelet activation, platelet aggregation inhibitors",
author = "Hart, {Robert G.} and Halperin, {Jonathan L.} and Weitz, {Jeffrey I.}",
note = "Funding Information: Dr. Hart serves as a consultant to and receives research funding from Bayer Healthcare . Dr. Halperin has chaired a data and safety monitoring board for a trial involving patients with peripheral artery disease for AstraZeneca. Dr. Weitz has been a consultant and received honoraria from Merck & Co. ",
year = "2014",
month = dec,
day = "9",
doi = "10.1016/j.jacc.2014.09.038",
language = "English",
volume = "64",
pages = "2327--2329",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier Inc.",
number = "22",
}